485 related articles for article (PubMed ID: 31573469)
21. Comparison of nintedanib-induced gastrointestinal adverse events between patients with systemic sclerosis-associated interstitial lung disease and idiopathic interstitial pneumonias.
Imai M; Okabayashi H; Akaike K; Hamada S; Masunaga A; Ichiyasu H; Sakagami T
Respir Investig; 2024 May; 62(3):317-321. PubMed ID: 38395006
[TBL] [Abstract][Full Text] [Related]
22. Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled Trial.
Maher TM; Mayes MD; Kreuter M; Volkmann ER; Aringer M; Castellvi I; Cutolo M; Stock C; Schoof N; Alves M; Raghu G;
Arthritis Rheumatol; 2021 Apr; 73(4):671-676. PubMed ID: 33142016
[TBL] [Abstract][Full Text] [Related]
23. Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs).
Joannes A; Voisin T; Morzadec C; Letellier A; Gutierrez FL; Chiforeanu DC; Le Naoures C; Guillot S; De Latour BR; Rouze S; Jaillet M; Crestani B; Wollin L; Jouneau S; Vernhet L
Pulm Pharmacol Ther; 2023 Dec; 83():102267. PubMed ID: 37972706
[TBL] [Abstract][Full Text] [Related]
24. Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: A Japanese population analysis of the SENSCIS trial.
Kuwana M; Ogura T; Makino S; Homma S; Kondoh Y; Saito A; Ugai H; Gahlemann M; Takehara K; Azuma A
Mod Rheumatol; 2021 Jan; 31(1):141-150. PubMed ID: 32243207
[TBL] [Abstract][Full Text] [Related]
25. Should we use nintedanib as early therapy in patients with SSc-ILD?
Zanatta E; Moccaldi B; Szucs G; Spagnolo P
Autoimmun Rev; 2024 Jan; 23(1):103463. PubMed ID: 37844857
[TBL] [Abstract][Full Text] [Related]
26. Nintedanib-mediated improvement in CT imaging in pulmonary fibrosis associated with systemic scleroderma.
Nishino K; Sasatani Y; Ohara G; Kagohashi K; Satoh H
Adv Respir Med; 2021; 89(5):528-531. PubMed ID: 34569613
[TBL] [Abstract][Full Text] [Related]
27. Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial.
Seibold JR; Maher TM; Highland KB; Assassi S; Azuma A; Hummers LK; Costabel U; von Wangenheim U; Kohlbrenner V; Gahlemann M; Alves M; Distler O;
Ann Rheum Dis; 2020 Nov; 79(11):1478-1484. PubMed ID: 32759258
[TBL] [Abstract][Full Text] [Related]
28. Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease.
Allanore Y; Khanna D; Smith V; Aringer M; Hoffmann-Vold AM; Kuwana M; Merkel PA; Stock C; Sambevski S; Denton CP;
Rheumatology (Oxford); 2024 Mar; 63(3):639-647. PubMed ID: 37294870
[TBL] [Abstract][Full Text] [Related]
29. Nintedanib Therapy Alone and Combined with Mycophenolate in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: Systematic Reviews and Meta-analysis.
Herman D; Ghazipura M; Barnes H; Macrea M; Knight SL; Silver RM; Montesi SB; Raghu G; Hossain T
Ann Am Thorac Soc; 2024 Mar; 21(3):474-485. PubMed ID: 37773000
[No Abstract] [Full Text] [Related]
30. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases.
Cottin V; Richeldi L; Rosas I; Otaola M; Song JW; Tomassetti S; Wijsenbeek M; Schmitz M; Coeck C; Stowasser S; Schlenker-Herceg R; Kolb M;
Respir Res; 2021 Mar; 22(1):84. PubMed ID: 33726766
[TBL] [Abstract][Full Text] [Related]
31. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
Gibson CD; Kugler MC; Deshwal H; Munger JS; Condos R
Lung; 2020 Aug; 198(4):597-608. PubMed ID: 32591895
[TBL] [Abstract][Full Text] [Related]
32. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis.
Hostettler KE; Zhong J; Papakonstantinou E; Karakiulakis G; Tamm M; Seidel P; Sun Q; Mandal J; Lardinois D; Lambers C; Roth M
Respir Res; 2014 Dec; 15(1):157. PubMed ID: 25496490
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: Subgroup analysis of the SENSCIS trial.
Azuma A; Chung L; Behera D; Chung M; Kondoh Y; Ogura T; Okamoto M; Swarnakar R; Zeng X; Zou H; Meng X; Gahlemann M; Alves M; Kuwana M;
Respir Investig; 2021 Mar; 59(2):252-259. PubMed ID: 33223487
[TBL] [Abstract][Full Text] [Related]
34. Integrative analysis of lung molecular signatures reveals key drivers of systemic sclerosis-associated interstitial lung disease.
Jung SM; Park KS; Kim KJ
Ann Rheum Dis; 2022 Jan; 81(1):108-116. PubMed ID: 34380701
[TBL] [Abstract][Full Text] [Related]
35. Disparate Interferon Signaling and Shared Aberrant Basaloid Cells in Single-Cell Profiling of Idiopathic Pulmonary Fibrosis and Systemic Sclerosis-Associated Interstitial Lung Disease.
Valenzi E; Tabib T; Papazoglou A; Sembrat J; Trejo Bittar HE; Rojas M; Lafyatis R
Front Immunol; 2021; 12():595811. PubMed ID: 33859634
[TBL] [Abstract][Full Text] [Related]
36. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
Wollin L; Maillet I; Quesniaux V; Holweg A; Ryffel B
J Pharmacol Exp Ther; 2014 May; 349(2):209-20. PubMed ID: 24556663
[TBL] [Abstract][Full Text] [Related]
37. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
Front Immunol; 2020; 11():1990. PubMed ID: 33013852
[TBL] [Abstract][Full Text] [Related]
38. Systemic Sclerosis Associated Interstitial Lung Disease and Nintedanib: A Rare Disease and a Promising Drug.
Kafle S; Thapa Magar M; Patel P; Poudel A; Cancarevic I
Cureus; 2021 Jul; 13(7):e16404. PubMed ID: 34414042
[TBL] [Abstract][Full Text] [Related]
39. Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases.
Cheng JZ; Wilcox PG; Glaspole I; Corte TJ; Murphy D; Hague CJ; Ryerson CJ
Respirology; 2017 Nov; 22(8):1592-1597. PubMed ID: 28544079
[TBL] [Abstract][Full Text] [Related]
40. Critical Role of LMCD1 in Promoting Profibrotic Characteristics of Lung Myofibroblasts in Experimental and Scleroderma-Associated Lung Fibrosis.
Bogatkevich GS; Atanelishvili I; Bogatkevich AM; Silver RM
Arthritis Rheumatol; 2023 Mar; 75(3):438-448. PubMed ID: 36103378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
